Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Michelle E, Maglio"'
Autor:
Paul G, Richardson, Susanna J, Jacobus, Edie A, Weller, Hani, Hassoun, Sagar, Lonial, Noopur S, Raje, Eva, Medvedova, Philip L, McCarthy, Edward N, Libby, Peter M, Voorhees, Robert Z, Orlowski, Larry D, Anderson, Jeffrey A, Zonder, Carter P, Milner, Cristina, Gasparetto, Mounzer E, Agha, Abdullah M, Khan, David D, Hurd, Krisstina, Gowin, Rammurti T, Kamble, Sundar, Jagannath, Nitya, Nathwani, Melissa, Alsina, R Frank, Cornell, Hamza, Hashmi, Erica L, Campagnaro, Astrid C, Andreescu, Teresa, Gentile, Michaela, Liedtke, Kelly N, Godby, Adam D, Cohen, Thomas H, Openshaw, Marcelo C, Pasquini, Sergio A, Giralt, Jonathan L, Kaufman, Andrew J, Yee, Emma, Scott, Pallawi, Torka, Amy, Foley, Mariateresa, Fulciniti, Kyle, Hebert, Mehmet K, Samur, Kelly, Masone, Michelle E, Maglio, Andrea A, Zeytoonjian, Omar, Nadeem, Robert L, Schlossman, Jacob P, Laubach, Claudia, Paba-Prada, Irene M, Ghobrial, Aurore, Perrot, Philippe, Moreau, Hervé, Avet-Loiseau, Michel, Attal, Kenneth C, Anderson, Nikhil C, Munshi, Hillard, Lazarus
Publikováno v:
N Engl J Med
BACKGROUND: In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until
Autor:
Paul G. Richardson, Michelle E. Maglio, Nelson J. Chao, Brandon M. Triplett, Mohamad Mohty, Vincent T. Ho, Fiona L Dignan
Publikováno v:
Expert Review of Clinical Pharmacology. 11:113-124
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable condition associated with endothelial-cell damage due to conditioning for hematopoietic stem-cell transplantation (HSCT) or chemotherapy without HSCT. Mortal
Autor:
Michelle E. Maglio, Robert F. Cornell, Melissa Alsina, Daniel J. Lenihan, Paul G. Richardson, John D. Groarke, Jacob P. Laubach, Kenneth H. Shain, Javid Moslehi, Michael G. Fradley
Publikováno v:
British Journal of Haematology. 180:271-275
Patients with multiple myeloma (MM) have improved treatment options, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Despite their efficacy, increased rates of cardiovascular (CV) complications occur in patients exposed to s
Publikováno v:
British journal of haematology. 181(4)
Multiple myeloma (MM) is the second most common haematological malignancy after non-Hodgkin lymphoma. Despite the improvement in outcomes over the last decade with the introduction of novel therapies, such as immunomodulatory agents (IMiDs) and prote
Autor:
Michelle E. Maglio, Paul G. Richardson, Jacob P. Laubach, Nikhil C. Munshi, Elizabeth O'Donnell, Irene M. Ghobrial, Kenneth C. Anderson, Claudia E. Paba-Prada, Matthew Weinstock, Noopur Raje, Wanling Xie, Robert L. Schlossman, Constantine S. Mitsiades, Edie Weller, Diane Warren, Cindy Varga
Publikováno v:
British Journal of Haematology. 169:843-850
Summary Proteasome inhibitors (PI) and immunomodulatory agents (IMIDs) have improved the overall survival (OS) of patients with multiple myeloma (MM), but concerns have been raised about increased incidence of extramedullary disease (EMD) after the c
Autor:
Michel, Attal, Valerie, Lauwers-Cances, Cyrille, Hulin, Xavier, Leleu, Denis, Caillot, Martine, Escoffre, Bertrand, Arnulf, Margaret, Macro, Karim, Belhadj, Laurent, Garderet, Murielle, Roussel, Catherine, Payen, Claire, Mathiot, Jean P, Fermand, Nathalie, Meuleman, Sandrine, Rollet, Michelle E, Maglio, Andrea A, Zeytoonjian, Edie A, Weller, Nikhil, Munshi, Kenneth C, Anderson, Paul G, Richardson, Thierry, Facon, Hervé, Avet-Loiseau, Jean-Luc, Harousseau, Philippe, Moreau, P, Zunic
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (14), pp.1311-1320. ⟨10.1056/NEJMoa1611750⟩
New England Journal of Medicine, 2017, 376 (14), pp.1311-1320. ⟨10.1056/NEJMoa1611750⟩
New England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (14), pp.1311-1320. ⟨10.1056/NEJMoa1611750⟩
New England Journal of Medicine, 2017, 376 (14), pp.1311-1320. ⟨10.1056/NEJMoa1611750⟩
International audience; BackgroundHigh-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc03257c51eb21024f9872b6210446a
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01557406
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01557406
Autor:
Gullu Gorgun, Michelle E. Maglio, Cindy Varga, Constantine S. Mitsiades, Irene M. Ghobrial, Noopur Raje, Anna Guidetti, Mary McKenney, Robert L. Schlossman, Claudia Paba Prada, Paul G. Richardson, Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Deborah Doss, Jacob P. Laubach
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1089-1108
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is uniq
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
Jesús F. San-Miguel, Jacob P. Laubach, Sagar Lonial, Philippe Moreau, Michelle E. Maglio, Paul G. Richardson
Publikováno v:
Pharmacological research. 117
Deacetylase enzymes remove acetyl groups from histone and nonhistone proteins. Dysregulation of deacetylase activity is a hallmark of malignancy, including multiple myeloma (MM). Deacetylase inhibitors (DACi) cause epigenetic modification and inhibit
Autor:
Ernst Holler, Dietger Niederwieser, Nancy A. Kernan, Selim Corbacioglu, Paul G. Richardson, Leslie Lehmann, Sergio Giralt, Michelle E. Maglio, Craig Maguire, Marco Sardella, Margaret Hoyle, Vincent T. Ho, Robert J. Soiffer, Enric Carreras
Publikováno v:
Expert Opinion on Drug Safety. 12:123-136
Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of chemotherapeutic conditioning used in preparation for hematopoietic stem-cell transplantation (SCT). Defibrot